-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2018, Li You monoclonal antibody of cutting by the US Food and Drug Administration approved the Bureau, as the phase III after concurrent chemoradiotherapy (CRT) non-small cell lung cancer ( NSCLC ) in patients with the consolidation of immune therapy.
2018, Li You monoclonal antibody of cutting by the US Food and Drug Administration approved the Bureau, as the phase III after concurrent chemoradiotherapy (CRT) non-small cell lung cancer ( NSCLC ) in patients with the consolidation of immune therapy.
Of the 37 patients, 13 patients started duvalizumab at a median of 20 days after completion of CRT.
Figure 1 Median PFS treated by different groups of patients
Of the 24 patients who completed CRT but did not use duvalizumab, 16 patients completed CRT only, and 8 patients completed CRT and were treated with induced or consolidated EGFR tyrosine kinase inhibitors (TKIs).
p p
In this study, NSCLC patients with EGFR mutations did not benefit from duvalizumab and may be more prone to irAEs.
NSCLC patients with EGFR mutations do not benefit from duvalizumab and may be more prone to irAEs.
Aredo, Jacqueline V.
et al.
Durvalumab for Stage IIIEGFR -Mutated NSCLC After Definitive Chemoradiotherapy.
Journal of Thoracic Oncology, Volume 16, Issue 6, 1030-1041 Durvalumab for Stage IIIEGFR -Mutated NSCLC After Definitive Chemoradiotherapy.
EGFR
leave a message here
